About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Eurasian Hematology-Oncology Group
http://www.ehog.net/
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Videos
8th Eurasian Hematology Oncology Summit
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Palliative & Supportive Care
COVID-19
Basic Science
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Lung
Business
7th Eurasian Hematology Oncology Summit
COVID-19
Leukemia
Lymphoma
Myeloma
MDS and MPN
Xth Eurasian Hematology-Oncology Congress
Breast
Lung
Hematologic Oncology
Gastrointestinal
Genitourinary
General Oncology
Sarcoma
Skin
Head & Neck
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
O
Early Relapsed Follicular Lymphoma: Is POD24 a Good OS Predictor? What Is the Best Management Approach for High-Risk Disease With POD?
By
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
FEATURING
Ozan Salim
By
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
FEATURING
Ozan Salim
9 views
January 18, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Lymphoma
24:13
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Low-Grade Lymphoproliferative Disorders: Does Bendamustine Improve P…
Feat.
A. Symeonidis
29:22
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Indolent Lymphomas: How to Define High TMB Patients? Does Reduced-Do…
Feat.
C. De Souza
20:43
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Early Relapsed Follicular Lymphoma: Is POD24 a Good OS Predictor? Wh…
Feat.
O. Salim
20:32
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Malignancy Associated Hemophagocytic Lymphohistiocytosis: Diagnosis …
Feat.
S. Kalayoglu Besisik
23:45
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
ASCT in MCL: Are There Patients Who Don't Benefit From ASCT? Do…
Feat.
E. Birtas Atesoglu
24:18
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Waldenstrom's Macroglobulinemia Updates: What Chemoimmunotherap…
Feat.
A. Ibrahim
12:17
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
NGS in DLBCL: Gene Mutations and Results, Statistic Analysis With SP…
Feat.
A. Ozcalimli
23:43
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Prospects for IO for Malignant Pleural Effusions: Secretome, Dampene…
Feat.
V. Donnenberg,
A. Donnenberg
22:39
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Lymphoblastic Lymphoma: How Effective Are ALL-Regimen Therapy and CH…
Feat.
A. Antipova
15:40
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
IO for R/R cHL: Optimal Treatment Regimen, Therapy Duration & Di…
Feat.
K. Lepik
23:43
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
DLBCL Updates: Should High-Risk Patients Be Treated With RCHOP? Does…
Feat.
C. Gisselbrecht
